Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 16, 2026Score 13/30231% above fair value
$116.35+4.35 (+3.88%)
Close on Nov 18, 2026Market cap $7.30BP/E –Yield –
Twist Bioscience revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Twist Bioscience's revenue for the twelve months ending Jun 30, 2026 was $431.80M, up 19.2% year over year. For fiscal 2025 it was $376.57M, up 20.3% from the year before. The highest annual figure on record is $376.57M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $376.57M | +20.3% |
| FY2024 | Sep 30, 2024 | $312.97M | +27.7% |
| FY2023 | Sep 30, 2023 | $245.11M | +20.4% |
| FY2022 | Sep 30, 2022 | $203.57M | +53.8% |
| FY2021 | Sep 30, 2021 | $132.33M | +46.9% |
| FY2020 | Sep 30, 2020 | $90.10M | +65.7% |
| FY2019 | Sep 30, 2019 | $54.39M | +113.9% |
| FY2018 | Sep 30, 2018 | $25.43M | +136.2% |
| FY2017 | Sep 30, 2017 | $10.77M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $118.38M | +23.2% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $110.72M | +19.3% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $103.70M | +16.9% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $99.01M | +16.9% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $96.06M | +17.9% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $92.79M | +23.2% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $88.71M | +24.1% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $84.71M | +26.5% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $81.46M | +27.8% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $75.30M | +25.1% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $71.50M | +31.8% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $66.95M | +16.8% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $63.74M | +13.6% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $60.18M | +25.0% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $54.24M | +29.1% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $57.31M | +51.0% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $56.11M | +60.2% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $48.13M | +54.2% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $42.02M | +49.2% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $37.95M | +17.0% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $35.02M | +65.1% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $31.20M | +61.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $28.16M | +64.1% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $32.43M | +106.1% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $21.21M | +55.9% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $19.30M | +42.3% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $17.16M | +49.4% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $15.74M | +87.2% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $13.60M | +107.9% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $13.56M | +119.9% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $11.49M | +166.5% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $8.41M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $6.54M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $6.17M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $4.31M | – |
See a number that looks wrong?